Identification of early changes in multiple biomarkers following CFTR modulator initiation in patients with cystic fibrosis
Therapeutic Advances in Respiratory Disease · 2025
DOI: 10.1177/17534666251376211 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2025. Verfasst von Pascal Heer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Pulmonology and Cystic Fibrosis Unit, Children's Hospital of Central Switzerland, Lucerne, Switzerland. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Aminophenols, Benzodioxoles. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondation Respirer, Cystic Fibrosis Switzerland.
Abstract (Originalsprache)
Background
There are currently no early parameters that allow prediction of long-term responses to Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator treatment on an individual level.
Objectives
To identify early parameters measured within 7 to 14 days after initiation of treatment with a CFTR modulator to assess CFTR modulator efficacy. Study design: Prospective observational study of patients diagnosed with CF who begin elexacaftor/tezacaftor/ivacaftor (ETI) therapy at 3 CF clinics in Switzerland (Geneva, Lausanne, Lucerne).
Methods
Standardized measurements were taken within 2 months prior to and 7 to 14 days after starting CFTR modulator treatment.
Results
ETI treatment was started on 47 patients [median age: 12 years] of whom 12 (26%) were switching from lumacaftor/ivacaftor ( n = 8) or tezacaftor/ivacaftor ( n = 4) to ETI. A significant early treatment effect was observed for BMI z -score ( p < 0.001) and inflammatory parameters (white blood cells ( p = 0.006), neutrophils ( p = 0.006), immunoglobulin G ( p = 0.012), and fecal calprotectin ( p = 0.002)). In CFTR functional assays, sweat chloride concentration and nasal potential difference testing [Δlow-chloride+isoproterenol, Sermet score, and Wilschanski index] improved significantly (all p < 0.001). Improvement was also observed in lung function (FVC, FEV 1 , MMEF 25-75 , LCI 2.5% ) (all p < 0.001). No changes were found for blood pressure, SpO 2 , respiratory rate, erythrocyte sedimentation rate, C-reactive protein, and fecal elastase.
Conclusion
This study identified clinical, biologic, and functional parameters showing treatment effect early after initiation of CFTR modulator therapy. These parameters may serve as potential predictors of long-term responses to CFTR modulator treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Pulmonology and Cystic Fibrosis Unit, Children's Hospital of Central Switzerland, Lucerne, Switzerland.
- Pediatric Pulmonology and Cystic Fibrosis Unit, Division of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Adult Cystic Fibrosis and CFTR-related disorders Center, Lung Transplant Center, Division of Pulmonology, Lausanne University Hospital and University of Lausanne, Switzerland.
- Pediatric Pulmonology and Cystic Fibrosis Unit, University Hospital of Geneva, Geneva, Switzerland.
- Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
ORCID-Profile: Pascal Heer, Angela Koutsokera, Anne Mornand, Nicolas Regamey, Sylvain Blanchon
Förderung
- Fondation Respirer
- Cystic Fibrosis Switzerland
Zitieren
APA
Heer, P., Fernandez Elviro, C., Koutsokera, A., Mornand, A., Rochat, I., Regamey, N., & Blanchon, S. (2025). Identification of early changes in multiple biomarkers following CFTR modulator initiation in patients with cystic fibrosis. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666251376211
Vancouver
Heer P, Fernandez Elviro C, Koutsokera A, Mornand A, Rochat I, Regamey N, et al. Identification of early changes in multiple biomarkers following CFTR modulator initiation in patients with cystic fibrosis. Therapeutic Advances in Respiratory Disease. 2025. doi:10.1177/17534666251376211
BibTeX
@article{Heer2025,
author = {Heer, Pascal and Fernandez Elviro, Clara and Koutsokera, Angela and Mornand, Anne and Rochat, Isabelle and Regamey, Nicolas and Blanchon, Sylvain},
title = {Identification of early changes in multiple biomarkers following CFTR modulator initiation in patients with cystic fibrosis},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2025},
doi = {10.1177/17534666251376211}
}
EUVIMED